Recent briefings through late June 2026 did not identify discrete Pfizer-specific corporate news events in the 30 days preceding this report's generation date of 2026-07-27. The broader macro environment over this period was characterised by heightened geopolitical uncertainty, which formed the backdrop against which institutional position changes in PFE were recorded. No company-specific announcements, product approvals, or regulatory actions were identified in the verified briefing data for this period [Brief - 2026-07-19] [Brief - 2026-07-11] [Brief - 2026-07-03].
Pfizer's trailing twelve-month revenue stood at $63.32 billion as of the most recent quarterly filing, reflecting year-over-year revenue growth of 5.37%. Net income over the same period was $7.49 billion, producing a net margin of 11.83% and an operating margin of 35.40%. Earnings per share declined 9.62% year-over-year. The company's P/E ratio was recorded at 18.73. Cash on hand was $1.70 billion against total debt of $64.46 billion, placing total debt at approximately 37.8 times the reported cash balance [SEC 10-Q - PFE - 2026-03-29].
Institutional ownership data indicates material position changes in the most recent 13F reporting period. Citadel reduced its PFE position by 17% [SEC 13F - Citadel - Q2 2026]. AQR Capital added 21% to its existing position [SEC 13F - AQR Capital - Q2 2026]. Millennium Management increased its holding by 9.9% [SEC 13F - Millennium - Q2 2026]. No insider transaction data from SEC Form 4 filings was included in the verified context for this report period.
The prevailing macro environment as of the report date shows the 10-year US Treasury yield at 4.71% and the 2-year yield at 4.37%, producing a normal yield curve with a spread of 34 basis points [FRED DGS10] [FRED DGS2]. This rate environment is reflected across broad equity and fixed income markets during the reporting period.
This report was generated in response to material institutional position changes identified across multiple large asset managers in the Q2 2026 13F filing cycle, as noted in the ownership section above.